RefleXion Medical Enhances Cancer Treatment with SCINTIX Therapy
![RefleXion Medical Enhances Cancer Treatment with SCINTIX Therapy](/images/blog/ihnews-RefleXion%20Medical%20Enhances%20Cancer%20Treatment%20with%20SCINTIX%20Therapy.jpg)
RefleXion Medical Enhances Cancer Treatment Accessibility
RefleXion Medical, a leading teranostic oncology company, has recently made headlines with the installation of its advanced RefleXion X1 platform, featuring the innovative SCINTIX biology-guided radiotherapy system. This pivotal move marks a significant milestone as the Beverly Hills Cancer Center (BHCC) becomes the first freestanding cancer center (FSCC) to adopt this groundbreaking technology.
Advancing Patient Care with Revolutionary Technology
Dr. Arash (Ari) Gabayan, Chief of Radiation Oncology and Imaging at BHCC, emphasizes the center's commitment to transforming cancer care through the integration of cutting-edge innovations. He expresses excitement about offering patients access to this transformative therapy, which utilizes the tumor's inherent biology to direct radiation accurately to the tumor target.
The Mechanism Behind SCINTIX Therapy
The SCINTIX system takes a revolutionary approach to treat patients. It employs signals emitted from a patient's own tumor to guide the radiation treatment process. After receiving a small injection of a unique PET tracer molecule, cancer cells uptake this tracer. Consequently, the RefleXion X1 detects these signals in real time, adjusting radiation delivery precisely to target the tumor, enhancing treatment accuracy while minimizing exposure to healthy tissues.
Conventional radiotherapy primarily relies on static imaging, which can limit its effectiveness. In contrast, SCINTIX therapy's dynamic response to the tumor's movements represents a significant advancement in delivering radiation safely and effectively.
Future of Reimbursement for Innovative Cancer Treatments
In a promising development for the field, the Centers for Medicare and Medicaid Services (CMS) has announced plans to expand reimbursement for SCINTIX therapy starting in 2025. This expansion includes introducing new billing codes for freestanding cancer centers and enhanced reimbursement for physicians, enabling broader accessibility to this novel therapy.
According to Todd Powell, president and CEO of RefleXion, this reimbursement revision is paramount as it encourages clinical practices to adopt advanced technologies and treatments. The gesture by CMS indicates a growing recognition of the need for innovative therapies that enhance patient outcomes in oncology.
Collaborative Initiatives for Comprehensive Cancer Care
BHCC has partnered with Select Healthcare Solutions, a medical technology solutions provider, to seamlessly integrate SCINTIX therapy into their comprehensive cancer treatment offerings. This collaboration showcases a strong commitment to ensuring that patients can benefit from the latest advancements in cancer care.
About RefleXion Medical
RefleXion Medical is at the forefront of developing and commercializing SCINTIX therapy, which is changing the landscape of cancer treatment. This innovative approach enables physicians to use biological signals as real-time coordination for external-beam radiotherapy. With promising indications for treating lung and bone tumors, SCINTIX therapy is positioning itself as a crucial component in many cancer treatment protocols.
Commitment to Research and Development
Alongside SCINTIX therapy, RefleXion is dedicated to studying broader indications for its groundbreaking radiotherapy systems, including the RefleXion X1, which can cater to all solid tumors. This commitment to research is critical for paving the way toward new treatment options that can significantly improve survival rates and quality of life for patients.
About Beverly Hills Cancer Center
Recognized for its exceptional care, Beverly Hills Cancer Center combines advanced clinical trials, innovative diagnostics, and cutting-edge treatment options. With a team of highly skilled physicians and a supportive environment, BHCC stands out as a leader in cancer diagnosis and treatment. The center’s commitment to integrating the latest medical technologies positions it well for continued success in enhancing patient care.
Frequently Asked Questions
What is SCINTIX therapy?
SCINTIX therapy is a revolutionary radiation treatment that uses the biological signals of cancer cells to guide the precise delivery of radiation beams to tumors.
How does SCINTIX therapy differ from traditional radiotherapy?
Unlike traditional methods, which rely on static imaging, SCINTIX therapy provides real-time treatment guidance based on the tumor's movements, improving treatment accuracy.
Where has SCINTIX therapy been implemented?
SCINTIX therapy has recently been installed at the Beverly Hills Cancer Center, making it the first freestanding cancer center to offer this advanced treatment.
What upcoming changes are there regarding reimbursement for SCINTIX therapy?
The Centers for Medicare and Medicaid Services (CMS) plans to expand reimbursement for SCINTIX therapy starting in 2025, introducing new billing codes.
Who developed the SCINTIX therapy technology?
RefleXion Medical developed SCINTIX therapy, aiming to enhance cancer treatment through innovative radiotherapy solutions.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.